Trial Profile
A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti PD-L1 chimeric switch receptor modified T-cell therapy Marino Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
- Indications Glioblastoma
- Focus Adverse reactions
- 22 Oct 2016 New trial record